87 related articles for article (PubMed ID: 15829299)
1. HIV-1 neutralization by chimeric CD4-CG10 polypeptides fused to human IgG1.
Meyuhas R; Noy H; Montefiori DC; Denisova G; Gershoni JM; Gross G
Mol Immunol; 2005 May; 42(9):1099-109. PubMed ID: 15829299
[TBL] [Abstract][Full Text] [Related]
2. Enhanced HIV-1 neutralization by a CD4-VH3-IgG1 fusion protein.
Meyuhas R; Noy H; Fishman S; Margalit A; Montefiori DC; Gross G
Biochem Biophys Res Commun; 2009 Aug; 386(2):402-6. PubMed ID: 19538939
[TBL] [Abstract][Full Text] [Related]
3. Janusin: new molecular design for bispecific reagents.
Traunecker A; Lanzavecchia A; Karjalainen K
Int J Cancer Suppl; 1992; 7():51-2. PubMed ID: 1428404
[TBL] [Abstract][Full Text] [Related]
4. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120.
Liu F; Bergami PL; Duval M; Kuhrt D; Posner M; Cavacini L
AIDS Res Hum Retroviruses; 2003 Jul; 19(7):597-607. PubMed ID: 12908937
[TBL] [Abstract][Full Text] [Related]
5. Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies.
Xiang SH; Doka N; Choudhary RK; Sodroski J; Robinson JE
AIDS Res Hum Retroviruses; 2002 Nov; 18(16):1207-17. PubMed ID: 12487827
[TBL] [Abstract][Full Text] [Related]
6. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
7. A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event.
McInerney TL; McLain L; Armstrong SJ; Dimmock NJ
Virology; 1997 Jul; 233(2):313-26. PubMed ID: 9217055
[TBL] [Abstract][Full Text] [Related]
8. Influence of heavy chain constant regions on antigen binding and HIV-1 neutralization by a human monoclonal antibody.
Cavacini LA; Emes CL; Power J; Desharnais FD; Duval M; Montefiori D; Posner MR
J Immunol; 1995 Oct; 155(7):3638-44. PubMed ID: 7561063
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites.
Kwong PD; Doyle ML; Casper DJ; Cicala C; Leavitt SA; Majeed S; Steenbeke TD; Venturi M; Chaiken I; Fung M; Katinger H; Parren PW; Robinson J; Van Ryk D; Wang L; Burton DR; Freire E; Wyatt R; Sodroski J; Hendrickson WA; Arthos J
Nature; 2002 Dec; 420(6916):678-82. PubMed ID: 12478295
[TBL] [Abstract][Full Text] [Related]
10. Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor.
Dey B; Del Castillo CS; Berger EA
J Virol; 2003 Mar; 77(5):2859-65. PubMed ID: 12584309
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel CD4i human monoclonal antibody Fab that neutralizes HIV-1 primary isolates from different clades.
Zhang MY; Shu Y; Sidorov I; Dimitrov DS
Antiviral Res; 2004 Mar; 61(3):161-4. PubMed ID: 15168796
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates.
Kessler JA; McKenna PM; Emini EA; Chan CP; Patel MD; Gupta SK; Mark GE; Barbas CF; Burton DR; Conley AJ
AIDS Res Hum Retroviruses; 1997 May; 13(7):575-82. PubMed ID: 9135875
[TBL] [Abstract][Full Text] [Related]
13. Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules.
Traunecker A; Schneider J; Kiefer H; Karjalainen K
Nature; 1989 May; 339(6219):68-70. PubMed ID: 2541344
[TBL] [Abstract][Full Text] [Related]
14. The chimeric mouse-human anti-CD4 Fab 13B8.2 expressed in baculovirus inhibits both antigen presentation and HIV-1 promoter activation.
Bès C; Cerutti M; Briant-Longuet L; Bresson D; Peraldi-Roux S; Pugnière M; Mani JC; Pau B; Devaux C; Granier C; Devauchelle G; Chardès T
Hum Antibodies; 2001; 10(2):67-76. PubMed ID: 11673661
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the exposure of induced HIV glycoprotein epitopes in a potential HIV pseudovirion vaccine.
Devitt G; Emerson V; Pisch T; Keppler OT; Bosch V
Vaccine; 2007 Mar; 25(12):2161-7. PubMed ID: 17241712
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.
Blish CA; Nedellec R; Mandaliya K; Mosier DE; Overbaugh J
AIDS; 2007 Mar; 21(6):693-702. PubMed ID: 17413690
[TBL] [Abstract][Full Text] [Related]
17. Selection and characterization of an HIV-1 gp120-binding affibody ligand.
Wikman M; Rowcliffe E; Friedman M; Henning P; Lindholm L; Olofsson S; Ståhl S
Biotechnol Appl Biochem; 2006 Sep; 45(Pt 2):93-105. PubMed ID: 16712522
[TBL] [Abstract][Full Text] [Related]
18. High frequencies of antibody responses to CD4 induced epitopes in HIV infected patients started on HAART during acute infection.
Robinson JE; Elliott DH; Martin EA; Micken K; Rosenberg ES
Hum Antibodies; 2005; 14(3-4):115-21. PubMed ID: 16720981
[TBL] [Abstract][Full Text] [Related]
19. Prevention of HIV-1 IIIB infection in chimpanzees by CD4 immunoadhesin.
Ward RH; Capon DJ; Jett CM; Murthy KK; Mordenti J; Lucas C; Frie SW; Prince AM; Green JD; Eichberg JW
Nature; 1991 Aug; 352(6334):434-6. PubMed ID: 1907354
[TBL] [Abstract][Full Text] [Related]
20. Characterization of antibody responses to purified HIV-1 gp120 glycoproteins fused with the molecular adjuvant C3d.
Koch M; Frazier J; Sodroski J; Wyatt R
Virology; 2005 Sep; 340(2):277-84. PubMed ID: 16051303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
